20 March, 2025
Published monthly, the newsletter will provide information of interest on the operation of the Biobank, the latest developments in the Biobank's work, and its collaboration with various IIS Aragón groups, among others.
28 February, 2025
The event will take place in the Sala de la Corona of the Pignatelli Building in Zaragoza at 16:30. Free admission with prior registration, the event will feature health professionals from the IIS Aragón, IACS, FEDER and the Aragonese health services.
10 February, 2025
Three researchers from the IIS Aragón are participating in this event organized by the San Valero Group in collaboration with the AraHealth and AraBiotech clusters, and with the Spanish Society of Bioinformatics and Computational Biology (SEBiBC).
3 February, 2025
The Auditorium of the University of Zaragoza hosted the world-renowned scientific event on Thursday 30 and Friday 31 January, with more than 500 attendees. Ángel Lanas, scientific director of the IIS Aragón, described the congress as 'spectacular'.
30 January 2025
The Auditorium of the University of Zaragoza will host this international congress organized by the IIS Aragón. It is being held for the first time in Spain and will be attended by more than 500 people on Thursday and Friday to discuss the future of medicine.
27 January 2025
The Seville Foundation 'La Colmena' announces the winning projects of its 2024 Research Grants, an annual initiative aimed at supporting innovative research in the fields of Neurodegeneration, Cancer and Longevity.
24 January 2025
The MED4CHILD questionnaire, created by a multidisciplinary team that includes researchers from the GENUD group (IIS Aragón and the University of Zaragoza), will optimize the monitoring of eating habits in childhood and will contribute to improving public health interventions aimed at preventing diet-related diseases.
17 January 2025
The Aspanoa Chair of the University of Zaragoza will finance eight researchers with more than 16.000 euros in this second edition of the Impulso con Aspanoa project. Researchers from the IIS Aragón are participating in one of the projects.
30 December, 2024
A Phase 3 clinical trial demonstrates that the combination of imlunestrant and abemaciclib improves progression-free survival in advanced ER+ HER2- breast cancer, regardless of genomic profile. The compound as monotherapy only shows benefits in patients with mutations in the ESR1 gene.